Related Experiment Video

Updated: Apr 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K

Breast cancer treatment and sulfotransferase

Xi-Wei Ji1, Tian-Yan Zhou, Yuan Lu

  • 1Institute of Clinical Pharmacology, Peking University First Hospital, Peking University , Beijing , China jjxxeezz@163.com.

Expert Opinion on Therapeutic Targets
|February 14, 2015
PubMed
Abstract

Insights

Targeting sulfotransferase (SULT) enzymes offers a novel strategy for breast cancer treatment by inactivating estrogen. Activating SULT may provide a new therapeutic avenue for hormone-dependent breast cancer.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Oncology

Background:

  • Excessive estrogen exposure is a known breast cancer risk factor.
  • Sulfotransferase (SULT)-mediated sulfonation inactivates estrogen, preventing estrogen receptor (ER) activation.
  • Nuclear receptors (NRs) regulate SULT expression, sensing endogenous and xenobiotic molecules.

Purpose of the Study:

  • To review SULT regulation by NRs and estrogen inactivation mechanisms.
  • To discuss the potential of SULT-targeted therapies for breast cancer.
  • To identify knowledge gaps for future research.

Main Methods:

  • Review of literature on SULT regulation by NRs.
  • Summary of estrogen inactivation pathways mediated by SULT.
  • Discussion of clinical applications and future research directions.

Main Results:

  • NRs play a key role in regulating SULT-mediated estrogen inactivation.
  • SULT induction is an effective method for estrogen inactivation.
  • Clinical application of SULT induction for breast cancer treatment is underexplored.

Conclusions:

  • Targeted activation of SULT presents a promising new therapeutic strategy for hormone-dependent breast cancer.
  • Further research is needed to explore the clinical efficacy of SULT-targeted therapies.
  • This approach offers an alternative to current antiestrogen and estrogen synthesis inhibitors.
Keywords:
breast cancerendocrine regulationestrogennuclear receptorsulfotransferase

More Related Videos

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

3.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Related Concept Videos

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
82
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K